People
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
As the end looms near for the embattled Theranos and founder Elizabeth Holmes, there has been new movement with the addition of a noted screenwriter for the planned film about the rise and fall of the beleaguered medtech company.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
The first Novartis executive has fallen in the wake of the $1.2 million payment to President Donald Trump’s attorney for consulting work.
Shares of San Diego-based aTyr Pharma are down nearly 20 percent this morning after the company announced a corporate restructuring plan that includes a 30 percent reduction of staff following failures of its preclinical ORCA program.
The idea of “fake news” that has become a hallmark of the political landscape has made its way into the biotech world. Venture capitalist Tim Draper, a longtime supporter of medtech company Theranos, blames the slow demise of the company on a “hyena” reporter.
Biotech companies tapped a number of new upper management and c-suite executives last week. BioSpace put together a roundup of some of the latest appointments in the industry, which includes a number of new chief executive officers hired to helm companies.
For the second time in less than one year, Akari Therapeutics is without a chief executive officer. David Horn Solomon abruptly resigned after being caught using the company credit card for personal purposes.
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regeneron Science Talent Search.
PRESS RELEASES